Pembrolizumab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13494 publications

Efficacy of maintenance therapy with or without pembrolizumab in patients with advanced gastric cancer after first-line chemotherapy

Efficacy of maintenance therapy with or without pembrolizumab in patients with advanced gastric cancer after first-line chemotherapy

Journal: Zhonghua yi xue za zhi

Published: September 07, 2026

Corrigendum to "The safety of extended dosing pembrolizumab when compared to traditional dosing: a review and meta-analysis of retrospective studies" [Lung Cancer 204 (2025) 108585].

Corrigendum to "The safety of extended dosing pembrolizumab when compared to traditional dosing: a review and meta-analysis of retrospective studies" [Lung Cancer 204 (2025) 108585].

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 05, 2026

Remarkable Response to Pembrolizumab in Metastatic Cancer of Unknown Primary.

Remarkable Response to Pembrolizumab in Metastatic Cancer of Unknown Primary.

Journal: Clinical laboratory

Published: September 04, 2026

Local control of RCC pancreatic metastases is obtained by angiogenesis inhibitors.

Local control of RCC pancreatic metastases is obtained by angiogenesis inhibitors.

Journal: Acta clinica Belgica

Published: September 03, 2026

Tissue-Agnostic Cancer Therapy Approvals.

Tissue-Agnostic Cancer Therapy Approvals.

Journal: Hematology/oncology clinics of North America

Published: September 02, 2026

DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

Journal: Future oncology (London, England)

Published: September 02, 2026

Pembrolizumab-associated myasthenia gravis in thymic tumors: A single-center case series and comparative analysis.

Pembrolizumab-associated myasthenia gravis in thymic tumors: A single-center case series and comparative analysis.

Journal: Journal of neuromuscular diseases

Published: September 01, 2026

Prevalence of High Tumor Mutational Burden Among Pediatric Patients With Solid Tumors.

Prevalence of High Tumor Mutational Burden Among Pediatric Patients With Solid Tumors.

Journal: Pediatric hematology and oncology

Published: August 31, 2026

Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.

Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.

Journal: Leukemia & lymphoma

Published: August 30, 2026

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Journal: Expert opinion on biological therapy

Published: August 29, 2026

Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review.

Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review.

Journal: JAMA oncology

Published: August 27, 2026

Efficacy and Safety of Viscum album L. in Patients With Triple-Negative Breast Cancer Receiving Immune Checkpoint Inhibitors: A Protocol for an Open-Label Randomized Clinical Trial.

Efficacy and Safety of Viscum album L. in Patients With Triple-Negative Breast Cancer Receiving Immune Checkpoint Inhibitors: A Protocol for an Open-Label Randomized Clinical Trial.

Journal: Integrative cancer therapies

Published: August 27, 2026

Showing 1-12 of 13,494

Last Updated: 09/26/2026